Suvorexant Low Dose (LD)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Primary Insomnia

Phase 3

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)

CompletedNCT01097629

Merck Sharp & Dohme LLCPrimary Insomnia

Start: 2010-05-03End: 2011-11-08Updated: 2019-08-28

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)

CompletedNCT01097616

Merck Sharp & Dohme LLCPrimary Insomnia

Start: 2010-05-05End: 2011-12-07Updated: 2018-09-21

Related Papers

Comparison of polysomnography in people with Alzheimer's disease and insomnia versus non-demented elderly people with insomnia

Sleep Medicine2022-12-0111 citations

How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?

2019-09-1110 citations

Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.

2018-10-0227 citations

Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts

SLEEP2017-11-0328 citations

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.

2017-03-0847 citations

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.

2017-03-0715 citations

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

2016-09-1552 citations